miR‑122‑5p suppresses the oncogenesis of PTC by inhibiting DUSP4 expression

Hu,Ning; Tian,Yanhua; Song,Yanmei; Zang,Leilei

doi:10.3892/mmr.2021.12007

miR‑122‑5p suppresses the oncogenesis of PTC by inhibiting DUSP4 expression

Authors:
- Ning Hu
- Yanhua Tian
- Yanmei Song
- Leilei Zang
View Affiliations

Affiliations: Department IV of General Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050005, P.R. China, Department II of Oncology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050005, P.R. China, Department of Infection Management/Public Health, Hebei People's Hospital, Shijiazhuang, Hebei 050057, P.R. China, Department V of General Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050005, P.R. China
Published online on: March 16, 2021 https://doi.org/10.3892/mmr.2021.12007
Article Number: 368
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs or miRs) play an important role in regulating the occurrence and development of papillary thyroid carcinoma (PTC). miR‑122‑5p is widely considered a tumour inhibitor, which has not been fully explored in PTC. Bioinformatics analysis identified dual specificity phosphatase 4 (DUSP4), a tumour promoter gene for PTC, as a downstream target of miR‑122‑5p. The aim of the present study was to investigate the role and molecular mechanism of miR‑122‑5p in PTC oncogenesis. In this study, the expression pattern of miR‑122‑5p in PTC cancer tissues and PTC cell lines was investigated via reverse transcription‑quantitative PCR. Furthermore, the roles of miR‑122‑5p in PTC were explored using gain‑of‑function and loss‑of‑function assays. The results revealed that the expression of miR‑122‑5p was significantly lower in PTC cancer tissues, especially in cancer tissues with significant invasion or metastasis. Overexpression of miR‑122‑5p caused by miR‑122‑5p mimics inhibited the proliferation, invasion, and migration of the PTC cell line K1, while knockdown of miR‑122‑5p by miR‑122‑5p inhibitors exhibited the opposite effect. Furthermore, in vivo assays revealed that miR‑122‑5p overexpression inhibited tumour growth. In addition, miR‑122‑5p was negatively correlated with DUSP4 expression in PTC cancer tissues. miR‑122‑5p overexpression inhibited DUSP4 expression in K1 cells, while miR‑122‑5p downregulation produced the inverse effect. Specifically, a luciferase reporter assay confirmed the binding sites of miR‑122‑5p on the 3'‑UTR of DUSP4, demonstrating the targeting effect of miR‑122‑5p on DUSP4. miR‑122‑5p inhibited the oncogenesis of PTC by targeting DUSP4, revealing the potential application value of miR‑122‑5p in the diagnosis and treatment of PTC.

View Figures

View References

1	Yang Z, Li G, Ding C, Sun W and Zhang J: Long non-coding RNA HULC exerts oncogenic activity on papillary thyroid cancer in vitro and in vivo. Artif Cells Nanomed Biotechnol. 48:326–335. 2020. View Article : Google Scholar : PubMed/NCBI
2	Wiltshire JJ, Drake TM, Uttley L and Balasubramanian SP: Systematic review of trends in the incidence rates of thyroid cancer. Thyroid. 26:1541–1552. 2016. View Article : Google Scholar : PubMed/NCBI
3	Wang DP, Tang XZ, Liang QK, Zeng XJ, Yang JB and Xu J: microRNA-599 promotes apoptosis and represses proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells via downregulation of Hey2-depentent Notch signaling pathway. J Cell Physiol. 235:2492–2505. 2020. View Article : Google Scholar : PubMed/NCBI
4	Han J, Zhang M, Nie C, Jia J, Wang F, Yu J, Bi W, Liu B, Sheng R, He G, et al: miR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1. Cell Death Dis. 10:1952019. View Article : Google Scholar : PubMed/NCBI
5	Ma J, Li T, Han X and Yuan H: Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma. J Cancer Res Clin Oncol. 144:205–214. 2018. View Article : Google Scholar : PubMed/NCBI
6	Xu Z, Liu G, Zhang M, Zhang Z, Jia Y, Peng L, Zhu Y, Hu J, Huang R and Sun X: miR-122-5p inhibits the proliferation, invasion and growth of bile duct carcinoma cells by targeting ALDOA. Cell Physiol Biochem. 48:2596–2606. 2018. View Article : Google Scholar : PubMed/NCBI
7	Xu X, Gao F, Wang J, Tao L, Ye J, Ding L, Ji W and Chen X: MiR-122-5p inhibits cell migration and invasion in gastric cancer by down-regulating DUSP4. Cancer Biol Ther. 19:427–435. 2018. View Article : Google Scholar : PubMed/NCBI
8	Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS and Arteaga CL: Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res. 73:6346–6358. 2013. View Article : Google Scholar : PubMed/NCBI
9	Hijiya N, Tsukamoto Y, Nakada C, Tung Nguyen L, Kai T, Matsuura K, Shibata K, Inomata M, Uchida T, Tokunaga A, et al: Genomic loss of DUSP4 contributes to the progression of intraepithelial neoplasm of pancreas to invasive carcinoma. Cancer Res. 76:2612–2625. 2016. View Article : Google Scholar : PubMed/NCBI
10	Chen M, Zhang J, Berger AH, Diolombi MS, Ng C, Fung J, Bronson RT, Castillo-Martin M, Thin TH, Cordon-Cardo C, et al: Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis. J Clin Invest. 129:215–222. 2019. View Article : Google Scholar : PubMed/NCBI
11	Gröschl B, Bettstetter M, Giedl C, Woenckhaus M, Edmonston T, Hofstädter F and Dietmaier W: Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation. Int J Cancer. 132:1537–1546. 2013. View Article : Google Scholar : PubMed/NCBI
12	Ma B, Shi R, Yang S, Zhou L, Qu N, Liao T, Wang Y, Wang Y and Ji Q: DUSP4/MKP2 overexpression is associated with BRAF(V600E) mutation and aggressive behavior of papillary thyroid cancer. Onco Targets Ther. 9:2255–2263. 2016.PubMed/NCBI
13	Heinemann FG, Tolkach Y, Deng M, Schmidt D, Perner S, Kristiansen G, Müller SC and Ellinger J: Serum miR-122-5p and miR-206 expression: Non-invasive prognostic biomarkers for renal cell carcinoma. Clin Epigenetics. 10:112018. View Article : Google Scholar : PubMed/NCBI
14	Cheng G, Li Y, Liu Z and Song X: The microRNA-429/DUSP4 axis regulates the sensitivity of colorectal cancer cells to nintedanib. Mol Med Rep. 23:12012.
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Masson D, Rioux-Leclercq N, Fergelot P, Jouan F, Mottier S, Théoleyre S, Bach-Ngohou K, Patard JJ and Denis MG: Loss of expression of TIMP3 in clear cell renal cell carcinoma. Eur J Cancer. 46:1430–1437. 2010. View Article : Google Scholar : PubMed/NCBI
17	Kong QF, Lv B, Wang B, Zhang XP, Sun HJ and Liu J: Association of von Willebrand factor (vWF) expression with lymph node metastasis and hemodynamics in papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci. 24:2564–2571. 2020.PubMed/NCBI
18	Huang Y, Yu S, Cao S, Yin Y, Hong S, Guan H, Li Y and Xiao H: MicroRNA-222 promotes invasion and metastasis of papillary thyroid cancer through targeting protein phosphatase 2 regulatory subunit B alpha expression. Thyroid. 28:1162–1173. 2018. View Article : Google Scholar : PubMed/NCBI
19	Lima CR, Geraldo MV, Fuziwara CS, Kimura ET and Santos MF: MiRNA-146b-5p upregulates migration and invasion of different papillary thyroid carcinoma cells. BMC Cancer. 16:1082016. View Article : Google Scholar : PubMed/NCBI
20	Ding C, Yu H, Shi C, Shi T, Qin H and Cui Y: MiR-let-7e inhibits invasion and magration and regulates HMGB1 expression in papillary thyroid carcinoma. Biomed Pharmacother. 110:528–536. 2019. View Article : Google Scholar : PubMed/NCBI
21	Zhou B, Xu J, Chen Y, Gao S, Feng X and Lu X: miR-200b/c-RAP1B axis represses tumorigenesis and malignant progression of papillary thyroid carcinoma through inhibiting the NF-κB/Twist1 pathway. Exp Cell Res. 387:1117852020. View Article : Google Scholar : PubMed/NCBI
22	Zhou P, Irving A, Wu H, Luo J, Aguirre J, Costa M, Khamsuree M, Gerads N and Liu W: Validation of MicroRNA-188-5p inhibition power on tumor cell proliferation in papillary thyroid carcinoma. Cell Transplant. 29:9636897209183002020. View Article : Google Scholar : PubMed/NCBI
23	Liu H, Chen X, Lin T, Chen X, Yan J and Jiang S: MicroRNA-524-5p suppresses the progression of papillary thyroid carcinoma cells via targeting on FOXE1 and ITGA3 in cell autophagy and cycling pathways. J Cell Physiol. 234:18382–18391. 2019. View Article : Google Scholar : PubMed/NCBI
24	Santiago K, Chen Wongworawat Y and Khan S: Differential MicroRNA-signatures in thyroid cancer subtypes. J Oncol. 2020:20523962020. View Article : Google Scholar : PubMed/NCBI
25	Jiang K, Li G, Chen W, Song L, Wei T, Li Z, Gong R, Lei J, Shi H and Zhu J: Plasma exosomal miR-146b-5p and miR-222-3p are potential biomarkers for lymph node metastasis in papillary thyroid carcinomas. Onco Targets Ther. 13:1311–1319. 2020. View Article : Google Scholar : PubMed/NCBI